ASCO 2022: Cutting-Edge Performances by Antibody-Drug Conjugates in the Treatment of Breast Cancer

Avan J. Armaghani, MD


June 14, 2022

Avan Armaghani, MD, eagerly reports in the wake of ASCO 2022 on two crucial trials concerning treatment for metastatic breast cancer (mBC). The first, TROPiCS-02, investigated the extension of the antibody-drug conjugate sacituzumab govitecan to the treatment of hormone receptor–positive breast cancer. The second, DESTINY-Breast04, applied the antibody-drug conjugate trastuzumab deruxtecan to HER2-low mBC.

Both agents performed positively in terms of progression-free survival, with the latter especially producing a far-reaching clinical implication — specifically, the confirmation of HER2-low as a therapeutically targetable population of patients with mBC.


Comments on Medscape are moderated and should be professional in tone and on topic. You must declare any conflicts of interest related to your comments and responses. Please see our Commenting Guide for further information. We reserve the right to remove posts at our sole discretion.